Page 1 | Search Results | Journal of Human Immunity

1-4 of 4

Sort by

Journal Articles

Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial

Toshinao Kawai, Mayumi Sako, Katsuhiro Arai, Takashi Ishikawa, Tomoko Toma, Taizo Wada, Yutaro Yada, Masataka Ishimura, Takehiko Doi, Satoshi Okada, Hiroshi Moritake, Kazushi Izawa, Masahiro Ueki, Eisuke Inoue, Hidefumi Nakamura, Masafumi Onodera

J Hum Immun (2026) 2 (5): e20250256.

https://doi.org/10.70962/jhi.20250256

Published: 23 June 2026

View article titled, Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial

Includes: Supplementary data

Journal Articles

Dried Blood Spot (DBS) Proteomic Analysis in Familial Hemophagocytic Lymphohistiocytosis: Exploring Pre-Symptomatic Disease Biology and the Feasibility of Newborn Screening

Hirofumi Shibata, Yuiko Hirata, Daisuke Nakajima, Ryo Konno, Motoko Higashiguchi, Hiroshi Nihira, Hiroshi Oue, Eitaro Hiejima, Kazushi Izawa, Hidenori Ohnishi, Junko Takita, Osamu Ohara, Yusuke Kawashima, Takahiro Yasumi

J Hum Immun (2026) 2 (JSIAD2026): eJSIAD2026abstract.45.

https://doi.org/10.70962/JSIAD2026abstract.45

Published: 04 June 2026

View article titled, Dried Blood Spot (DBS) Proteomic Analysis in Familial Hemophagocytic Lymphohistiocytosis: Exploring Pre-Symptomatic Disease Biology and the Feasibility of Newborn Screening

Journal Articles

Interim Safety and Efficacy Outcomes of an Open-Label Long-Term Extension Study of Treatment with PI3Kδ Inhibitor Leniolisib in Pediatric Patients Aged 4-11 Years with Activated PI3Kδ Syndrome (APDS)

V. Koneti Rao, Manish J. Butte, Bénédicte Neven, Michaela Semeraro, Yael Gernez, Shanmuganathan Chandrakasan, Hirokazu Kanegane, Takahiro Yasumi, Kazushi Izawa, Alanvin Orpia, Ladan Foruraghi, Lauren Pauls, Lavenda Chirombo Kluczynski, Jason Bradt, Leisa Waynick, Anurag Relan, Gulbu Uzel

J Hum Immun (2026) 2 (CIS2026): eCIS2026abstract.217.

https://doi.org/10.70962/CIS2026abstract.217

Published: 01 May 2026

View article titled, Interim Safety and Efficacy Outcomes of an Open-Label Long-Term Extension Study of Treatment with PI3Kδ Inhibitor Leniolisib in Pediatric Patients Aged 4-11 Years with Activated PI3Kδ Syndrome (APDS)

Includes: Supplementary data

Journal Articles

Primary and Safety Outcomes of a Phase 3 Open-Label, Single-Arm, 12-Week Study of Treatment with PI3Kδ Inhibitor Leniolisib in Pediatric Patients Aged 4–11 Years with Activated PI3Kδ Syndrome (APDS)

V. Rao, Manish J. Butte, Bénédicte Neven, Michaela Semeraro, Yael Gernez, Shanmuganathan Chandrakasan, Hirokazu Kanegane, Takahiro Yasumi, Kazushi Izawa, Alanvin Orpia, Ladan Foruraghi, Lauren Pauls, Lavenda Chirombo Kluczynski, Jason Bradt, Anurag Relan, Gulbu Uzel

J Hum Immun (2025) 1 (CIS2025): CIS2025abstract.6.

https://doi.org/10.70962/CIS2025abstract.6

Published: 25 April 2025

View article titled, Primary and Safety Outcomes of a Phase 3 Open-Label, Single-Arm, 12-Week Study of Treatment with PI3Kδ Inhibitor Leniolisib in Pediatric Patients Aged 4–11 Years with Activated PI3Kδ Syndrome (APDS)

Update search

NARROW

Format

Subjects

Journal

Article Type

Date

Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial

Dried Blood Spot (DBS) Proteomic Analysis in Familial Hemophagocytic Lymphohistiocytosis: Exploring Pre-Symptomatic Disease Biology and the Feasibility of Newborn Screening

Interim Safety and Efficacy Outcomes of an Open-Label Long-Term Extension Study of Treatment with PI3Kδ Inhibitor Leniolisib in Pediatric Patients Aged 4-11 Years with Activated PI3Kδ Syndrome (APDS)

Primary and Safety Outcomes of a Phase 3 Open-Label, Single-Arm, 12-Week Study of Treatment with PI3Kδ Inhibitor Leniolisib in Pediatric Patients Aged 4–11 Years with Activated PI3Kδ Syndrome (APDS)

Email alerts

Update search

Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial

Dried Blood Spot (DBS) Proteomic Analysis in Familial Hemophagocytic Lymphohistiocytosis: Exploring Pre-Symptomatic Disease Biology and the Feasibility of Newborn Screening

Interim Safety and Efficacy Outcomes of an Open-Label Long-Term Extension Study of Treatment with PI3Kδ Inhibitor Leniolisib in Pediatric Patients Aged 4-11 Years with Activated PI3Kδ Syndrome (APDS)

Primary and Safety Outcomes of a Phase 3 Open-Label, Single-Arm, 12-Week Study of Treatment with PI3Kδ Inhibitor Leniolisib in Pediatric Patients Aged 4–11 Years with Activated PI3Kδ Syndrome (APDS)

Email alerts

Sharing Unavailable